Has Erdafitinib been included in medical insurance reimbursement?

Erdafitinib (Erdafitinib) is an FGFR inhibitor that has attracted much attention in the field of precision tumor treatment in recent years. It has been approved for marketing in China under the name of Erdafitinib Tablets (BALVERSA). The main indication of this drug is to treat patients with advanced or recurrent urothelial cancer (bladder cancer) carrying FGFR2 or FGFR3 gene alterations. The efficacy of these patients after traditional chemotherapy or immunotherapy is often unsatisfactory. Erdafitinib can inhibit the growth of tumor cells by directly targeting the FGFR signaling pathway, thus providing a new option for precision medicine. There are also international studies exploring its potential application in other tumor types, such as some cholangiocarcinomas or other solid tumors related to FGFR mutations, which means that the scope of indications may be further expanded in the future.

After being launched in China, the common specifications of erdafitinib include5mg 28 tablets, 3mg 56 tablets and 4mg*28 tablets, but it has not yet been included in the national medical insurance directory. This means that patients need to pay for the full amount of medication out of their own pocket, which imposes a heavy financial burden. Due to the short time to market and limited market circulation channels, many patients will choose to purchase original drugs through Hong Kong pharmacies or regular cross-border pharmacies, and their prices are often more than 20,000 yuan. Some generic drugs of the Lao version and the Bangladeshi version are gradually being used in the market. The price difference is obvious, and they are more suitable for some patient groups with limited financial affordability. However, when using generic drugs, you must follow the guidance of your doctor and ensure that the source of the drug is regular to avoid quality issues affecting the therapeutic effect.

In terms of medical insurance, although erdafitinib has not yet entered the scope of national medical insurance reimbursement, as the national drug negotiation mechanism continues to advance, the drug may reduce the financial burden of patients through medical insurance access in the future. In recent years, China has gradually included a variety of tumor-targeted drugs into the medical insurance catalog, benefiting more patients. The industry generally believes that with the accumulation of more real-world data and increasing patient demand, it is only a matter of time before erdafitinib enters medical insurance.

Reference materials：https://www.balversa.com/